Ultragenyx Pharmaceutical(US:RARE) Prnewswire·2026-02-19 01:49Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.) [1] - Investors have until April 6, 2026, to file for lead plaintiff status [1] Allegations - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, downplaying the risk of failure in achieving statistically significant results in the Phase III Orbit study [1] - It is claimed that Ultragenyx's optimism regarding the study's results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [1] - The lawsuit asserts that the positive statements made by the company about its business and prospects were materially misleading and lacked a reasonable basis [1] Investor Actions - Investors can retain counsel of their choice, contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, or file to be lead plaintiff by the April 6, 2026 deadline [1] - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [1]